| Analysis | Metabolite Name | Measured Value | Units | Group |
|---|---|---|---|---|
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.5997 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.6750 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.6832 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.6888 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.7266 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.7278 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.7294 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.7326 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.7441 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.7474 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.7494 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.7923 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8031 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8212 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8251 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8261 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8282 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8310 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8401 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8434 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8492 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8585 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8715 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8721 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8776 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8842 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.8986 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9000 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9004 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9085 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9086 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9099 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9107 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9112 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9185 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9206 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9260 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9283 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9318 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9320 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9432 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9577 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9653 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9707 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9748 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9757 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9784 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9830 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9856 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9872 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9928 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9995 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 0.9998 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0002 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0015 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0074 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0078 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0094 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0148 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0318 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0361 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0401 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0465 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0670 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0735 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0782 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0805 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0825 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0932 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0944 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.0990 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1087 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1125 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1169 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1172 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1281 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1382 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1490 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1540 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1632 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1644 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1703 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1773 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1905 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.1954 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2006 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2106 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2196 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2210 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2229 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2230 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2272 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2326 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2336 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2411 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2437 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.2924 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.3131 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.3196 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.3396 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.3491 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.3899 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.3913 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.4257 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.6153 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1,2-dipalmitoyl-GPC (16:0/16:0) | 1.7464 | Peak area | Diabetic non neuropathy |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|